’
C4 Therapeutics, a leader in the development of targeted protein degradation therapies, has announced its plans to present preliminary clinical data from the Phase 1 monotherapy trial of CFT1946 at the upcoming European Society for Medical Oncology (ESMO) Congress 2024. The announcement comes with the release of an abstract that showcases a favorable safety profile along with early evidence of anti-tumor activity associated with CFT1946.
The ESMO Congress, one of the most prestigious events for oncology professionals, will take place from insert date in insert location. CFT1946 is designed to selectively degrade proteins that drive cancer progression, making it a potentially groundbreaking treatment for various malignancies. The Phase 1 trial aims to evaluate the safety, tolerability, and efficacy of CFT1946 in patients with insert specific cancer types, and the research has generated considerable interest within the oncology community.
According to the preliminary data, CFT1946 demonstrated a robust safety profile, with a manageable incidence of adverse events reported among initial trial participants. Importantly, the abstract details significant evidence for anti-tumor activity, suggesting that the compound may hold promise as an effective treatment option for patients who have limited available therapies.
We are excited to share these early findings at the ESMO Congress, which highlight the potential of CFT1946 as a treatment for patients with challenging cancer diagnoses, said insert name
Comments